For the first time in many years, (gasp!) I diversified a bit. I joined the crowd and bought ARKG earlier today.
My own thesis is this:
Wars historically bring leaps in technology. For example, radar, jet planes, rocketry advances and more came out of WWII. This is due to a life-and-death urgency combined with epic spending.
Today there is a global war on the pandemic accompanied by just such urgency and spending in medical, biotech and related areas. I expect great strides in these areas and specifically want exposure to these areas in my portfolio.
However, I don’t have anything like the knowledge I brought to my TSLA investment when it comes to medical and biotech. I am aware how challenging biotech has been for VC’s. Since the thinking at ARK aligns with my own on the things I do know, I’m willing to go with them on the things I don’t.
So, I’m content to let ARKG ferret out and evaluate the genomic opportunities and to compensate them for doing so.
Not exactly what you’re asking, but it’s how I think about it.